Nurix Therapeutics 

Yahoo Finance • 7 months ago

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete responses in a heavily pretreated relapsed/... Full story

Yahoo Finance • 8 months ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Nurix Therapeutics, Inc. (NASDAQ: NRIX) (“Nurix”) on behalf of the company’s investors. Since July 2023, shares of Nurix’s common stock h... Full story

Yahoo Finance • 8 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story

Yahoo Finance • 8 months ago

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story

Yahoo Finance • 8 months ago

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story

Yahoo Finance • 9 months ago

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment Achieved an additional $8 million in research milestones for the quarter, resulting in milest... Full story

Yahoo Finance • 10 months ago

11 Cheap Small-Cap Stocks to Buy Before the Next Breakout

In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap stocks and the latest events in the stock market, then take a look at 5 Cheap Small-Ca... Full story

Yahoo Finance • 12 months ago

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Received $20 million licensing payment fro... Full story

Yahoo Finance • last year

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuselarge B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated in patients with mantle cell lymphoma (... Full story

Yahoo Finance • last year

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and... Full story

Yahoo Finance • last year

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights specificity and potency of NX-5948 and superio... Full story

Yahoo Finance • last year

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation pipeline with Gilead in rheumatoid arthri... Full story

Yahoo Finance • last year

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies a... Full story

Yahoo Finance • last year

Gilead Exercises First License Option Under Agreement With Nurix Therapeutics

https://cdn.benzinga.com/files/images/story/2023/03/20/gild.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational... Full story

Yahoo Finance • last year

Nurix’s stock rallies on Gilead’s option

MARKET PULSE Shares of Nurix Therapeutics Inc. (NRIX) gained about 6% in premarket trading on Monday after Gilead Sciences Inc. (GILD) said it exercised the option to exclusively license Nurix’s targeted protein degrader molecule, which is... Full story

Yahoo Finance • last year

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies a... Full story

Yahoo Finance • last year

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies a... Full story

Yahoo Finance • last year

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical programs and partnered preclinical progra... Full story

Yahoo Finance • last year

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies an... Full story

Yahoo Finance • 2 years ago

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resistance to both c... Full story